This website uses cookies
This website uses cookies. For further information on how we use cookies you can read our Privacy and Cookie notice
This website uses cookies. For further information on how we use cookies you can read our Privacy and Cookie notice
In stock
Easy Return, Quick Refund.Details
QABETE ENTERPRISES
96%Seller Score
62 Followers
Shipping speed: Excellent
Quality Score: Excellent
Customer Rating: Good
"Bad Blood: Secrets and Lies in a Silicon Valley Startup" by John Carreyrou is a gripping investigative nonfiction book that chronicles the rise and dramatic fall of Theranos, a biotech startup founded by Elizabeth Holmes. The company promised revolutionary blood-testing technology that could run numerous tests from just a tiny drop of blood, but the technology was fundamentally flawed and unreliable.
Theranos and Elizabeth Holmes:
Founded in 2003 by Holmes, Theranos attracted massive investment and was valued at around $9 billion, making Holmes a Silicon Valley icon often compared to Steve Jobs. However, the company’s core technology never worked as claimed.
Deception and Fraud:
The book reveals how Theranos misled investors, partners, and patients, using false claims, manipulated test results, and secretive practices to hide the truth about their technology’s failures.
Whistleblowers and Investigation:
Carreyrou, a Wall Street Journal journalist, broke the story after receiving tips from brave whistleblowers inside the company. His reporting exposed the deception despite intense legal pressure and attempts to silence him.
Corporate Culture and Leadership:
The book details a toxic work environment under Holmes and COO Sunny Balwani, marked by intimidation, secrecy, and ruthless suppression of dissent.
Impact and Legacy:
Theranos’s collapse led to regulatory investigations, criminal charges against Holmes and Balwani, and widespread reflection on Silicon Valley’s culture of hype and unchecked ambition.
It is a cautionary tale about the dangers of blind faith in charismatic leaders and disruptive technology without rigorous scientific validation.
The book highlights the importance of ethics, transparency, and accountability in healthcare and business.
It has been critically acclaimed, winning the 2018 Financial Times and McKinsey Business Book of the Year Award.
"Bad Blood: Secrets and Lies in a Silicon Valley Startup" by John Carreyrou is a gripping investigative nonfiction book that chronicles the rise and dramatic fall of Theranos, a biotech startup founded by Elizabeth Holmes. The company promised revolutionary blood-testing technology that could run numerous tests from just a tiny drop of blood, but the technology was fundamentally flawed and unreliable.
Theranos and Elizabeth Holmes:
Founded in 2003 by Holmes, Theranos attracted massive investment and was valued at around $9 billion, making Holmes a Silicon Valley icon often compared to Steve Jobs. However, the company’s core technology never worked as claimed.
Deception and Fraud:
The book reveals how Theranos misled investors, partners, and patients, using false claims, manipulated test results, and secretive practices to hide the truth about their technology’s failures.
Whistleblowers and Investigation:
Carreyrou, a Wall Street Journal journalist, broke the story after receiving tips from brave whistleblowers inside the company. His reporting exposed the deception despite intense legal pressure and attempts to silence him.
Corporate Culture and Leadership:
The book details a toxic work environment under Holmes and COO Sunny Balwani, marked by intimidation, secrecy, and ruthless suppression of dissent.
Impact and Legacy:
Theranos’s collapse led to regulatory investigations, criminal charges against Holmes and Balwani, and widespread reflection on Silicon Valley’s culture of hype and unchecked ambition.
It is a cautionary tale about the dangers of blind faith in charismatic leaders and disruptive technology without rigorous scientific validation.
The book highlights the importance of ethics, transparency, and accountability in healthcare and business.
It has been critically acclaimed, winning the 2018 Financial Times and McKinsey Business Book of the Year Award.
1 BOOK
This product has no ratings yet.
/product/62/8501523/1.jpg?6687)